Table 3.
Antibiotic resistance and eradication efficacies of hybrid therapy for Helicobacter pylori eradication
| First author, year | Region | Cases (n) | Duration (d) | Cure rate of ITT (%) | Cure rate of PP (%) | Susceptibility test (n) | Antibiotic resistance rate (%) | Cure rate of subgroups (% (n/n)) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMO | CLA | MET | CLA and MET | Neither CLA-R or MET-R | Isolated MET-R | Isolated CLA-R | Dual CLA-R and MET-R | |||||||
| Hsu, 2011[6] | Taiwan, China | 117 | 7 + 7 | 97.4 | 99.1 | 57 | 1.8 | 7.0 | 56.1 | 7.0 | 100 (25/25) | 100 (28/28) | 0 (0/0) | 100 (4/4) |
| Molina-Infante, 2013[10] | Spain/Italy | 171 | 7 + 7 | 90.0 | 92.0 | 34 | 0 | 23.5 | 33.0 | 8.8 | 100 (18/18) | 87.5 (7/8) | 100 (5/5) | 33.3 (1/3) |
| Wu, 2014[12] | Taiwan, China | 77 | 3 + 7 | 81.8 | 95.0 | 29 | 0 | 9.8 | 30.4 | 4.3 | 100 (21/21) | 100 (4/4) | 50 (1/2) | 100 (2/2) |
| Wu, 2014[12] | Taiwan, China | 73 | 5 + 7 | 86.3 | 95.1 | 34 | 0 | 9.8 | 30.4 | 4.3 | 100 (19/19) | 100 (12/12) | 100 (2/2) | 0 (0/1) |
| Wu, 2014[12] | Taiwan, China | 70 | 7 + 7 | 85.7 | 93.4 | 29 | 0 | 9.8 | 30.4 | 4.3 | 100 (19/19) | 100 (8/8) | 100 (1/1) | 100 (1/1) |
| Chen, 2015[8] | Taiwan, China | 88 | 7 + 7 | 92.0 | 96.4 | 65 | 0 | 15.3 | 37.9 | 8.9 | 94.3 (33/35) | 95.5 (21/22) | 100 (4/4) | 100 (4/4) |
| Pooled-data analysis | 596 | 248 | 98.5 (135/137) | 97.6 (80/82) | 92.9 (13/14) | 80.0 (12/15) | ||||||||
AMO: Amoxicillin; CLA: Clarithromycin; ITT: Intention-to-treat; MET: Metronidazole; PP: Per-protocol; R: Resistance; d: Days.